PT  - JOURNAL ARTICLE
AU  - Bhattacharyya, Arinjita
AU  - Chakraborty, Tanujit
AU  - Rai, Shesh N.
TI  - Stochastic forecasting of COVID-19 daily new cases across countries with a novel hybrid time series model
AID  - 10.1101/2020.10.01.20205021
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.10.01.20205021
4099  - http://medrxiv.org/content/early/2021/05/02/2020.10.01.20205021.short
4100  - http://medrxiv.org/content/early/2021/05/02/2020.10.01.20205021.full
AB  - An unprecedented outbreak of the novel coronavirus (COVID-19) in the form of peculiar pneumonia has spread globally since its first case in Wuhan province, China, in December 2019. Soon after, the infected cases and mortality increased rapidly. The future of the pandemic’s progress was uncertain, and thus, predicting it became crucial for public health researchers. These future predictions help the effective allocation of health care resources, stockpiling, and help in strategic planning for clinicians, government authorities, and public health policymakers after understanding the extent of the effect. The main objective of this paper is to develop a hybrid forecasting model that can generate real-time out-of-sample forecasts of COVID-19 outbreaks for five profoundly affected countries, namely the USA, Brazil, India, UK, and Canada. A novel hybrid approach based on the Theta method and Autoregressive neural network (ARNN) model, named Theta-ARNN (TARNN) model, is developed. Daily new cases of COVID-19 are nonlinear, non-stationary, and volatile; thus a single specific model cannot be ideal for future prediction of the pandemic. However, the newly introduced hybrid forecasting model with an acceptable prediction error rate can help healthcare and government for effective planning and resource allocation. The proposed method outperforms traditional univariate and hybrid forecasting models for the test data sets on an average.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot applicable.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No trials are done in this paper.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and codes are available at: https://github.com/arinjita9/COVID-19-Forecasting-by-TARNN- https://github.com/arinjita9/COVID-19-Forecasting-by-TARNN-